Gapping up
In reaction to strong earnings/guidance:
- QRTEA +6.4%, FOLD +4%
Other news:
- NKTR +7.8% (presents data from first-in-human Phase 1a study on novel t regulatory cell stimulator; was safe and well tolerated in this first-in-human study consistent with prior reported results)
- SPWR +5.7% (plans to separate into two independent, complementary, strategically-aligned and publicly-traded companies -- SunPower and Maxeon Solar Technologies)
- OCUL +3.9% (announces operational restructuring plan and strategic update)
- AL +1.9% (initiates portfolio sale of 19 aircraft to Thunderbolt III Aircraft Lease Limited)
- AKBA +1.7% (reports 52-week efficacy and safety data for Vadadustat; each study met its primary endpoint)
- GWPH +0.5% (receives positive NICE recommendation for Epidyolex oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy)
Analyst comments:
- MR +1.6% (upgraded to Outperform at Imperial Capital)
- ROST +0.9% (initiated with an Outperform at RBC Capital Mkts)
- HPE +0.7% (upgraded to Neutral from Sell at UBS)
- TEX +0.6% (upgraded to Outperform from Neutral at Robert W. Baird)